Editorial: biomarkers in HBV and prediction of treatment response

dc.contributor.author	Ridruejo, Ezequiel.
dc.date.accessioned	2023-08-11T16:02:31Z
dc.date.available	2023-08-11T16:02:31Z
dc.date.issued	2021-01
dc.identifier.citation	Aliment Pharmacol Ther . 2021 Jan;53(2):332-333.	es
dc.identifier.issn	217-369
dc.identifier.uri	https://riu.austral.edu.ar/handle/123456789/2266
dc.description	Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/apt.16171	es
dc.description.abstract	Hepatitis B cure is clinically defined as persistently undetectable HBsAg and hepatitis B virus (HBV) DNA in serum, with or without seroconversion to hepatitis B surface antibody (anti-HBs). Several definitions of HBV cure have been proposed, based on laboratory findings.1,2 Prediction of treatment response is a key issue in HBV management. Baseline and on-treatment predictors are needed as stopping rules, especially for pegylated interferon (Peg-IFN). Several new biomarkers such as HBV RNA, quantitative HBsAg (qHBsAg) and quantitative HBV core-related antigen (qHBcrAg) have been evaluated to predict HBeAg and HBsAg loss and relapse after cessa-tion of nucleos(t)ide analogues (NAs).1	es
dc.language.iso	en	es
dc.publisher	Wiley	es
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	HBV.	es
dc.subject	biomarkers in HBV.	es
dc.subject	Prediction of treatment response.	es
dc.title	Editorial: biomarkers in HBV and prediction of treatment response	es
dc.type	Article	es

Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional